Rising Prevalence of Blood Disorders and Chronic Diseases
The increasing prevalence of blood disorders and chronic diseases globally is a major factor driving the growth of the immunohematology market. Conditions such as anemia, hemophilia, and thalassemia, along with chronic diseases like diabetes and cardiovascular disorders, require frequent blood testing, transfusion support, and accurate compatibility assessment. According to the World Health Organization, as of 2023, approximately 30.7% of women aged 15 - 49 and nearly 40% of children worldwide are affected by anemia, many of whom require ongoing hematological monitoring and, in severe cases, blood transfusions. In the United States, data from the Centers for Disease Control and Prevention indicates that around 1 in 76 individuals is affected by a blood disorder, creating sustained demand for immunohematology testing, including blood typing and antibody screening.
The global burden of hematological malignancies further strengthens market demand. In 2024, approximately 4.6 million cases of blood cancers were projected worldwide, with leukemia being a major contributor. For example, data from the World Health Organization reported over 474,000 new leukemia cases in 2020, many of which require continuous transfusion support and precise compatibility testing. Additionally, sickle cell disease (SCD) affected an estimated 7.74 million people globally as of 2021. In high-prevalence regions such as India, which accounts for a significant share of global SCD births, government initiatives like the National Sickle Cell Elimination Program aim to screen millions of individuals, thereby increasing the demand for immunohematology reagents and diagnostic instruments.
Recent developments, including the introduction of automated blood typing systems and the expansion of blood banking infrastructure in emerging economies, are further supporting market growth. The rising burden of blood disorders particularly in regions such as Sub-Saharan Africa and South Asia continues to emphasize the need for advanced and scalable immunohematology solutions. Overall, the growing incidence of blood-related and chronic diseases remains a key driver, accelerating the adoption of sophisticated immunohematology diagnostics and improving transfusion safety and patient outcomes worldwide.
Automation and technological advancement
Automation and technological advancements in immunohematology analyzers have significantly accelerated the growth of the global immunohematology market, driven by the increasing need for precise, rapid, and reliable blood typing and compatibility testing. Traditional manual methods, such as tube testing, are labor-intensive, time-consuming, and prone to human error. In contrast, automated analyzers leverage advanced technologies, including microplate systems, computer-assisted interpretation, and integrated software platforms, to deliver higher accuracy and operational efficiency. Modern fully automated systems, such as the ORTHO VISION Max from Ortho Clinical Diagnostics and the Erytra Eflexis from Grifols, are capable of processing approximately 200–300 tests per day, significantly improving laboratory throughput. Studies indicate that automation can reduce manual intervention by up to 85-90%, enabling laboratory personnel to focus on complex cases rather than routine testing. Similarly, platforms such as the Qwalys-3 from Grifols and the Galileo System from Bio-Rad Laboratories have streamlined blood bank workflows, reducing turnaround times from hours to minutes.
Further technological advancements include the integration of artificial intelligence (AI) and machine learning algorithms, which enhance interpretative accuracy, particularly in complex serological cases. Automated analyzers now incorporate digital imaging and high-throughput capabilities, allowing laboratories to handle large sample volumes with minimal manual intervention. Recent industry developments also highlight that companies such as Ortho Clinical Diagnostics and Beckman Coulter are introducing next-generation systems equipped with features like barcode scanning, automated reagent handling, and real-time data management. These innovations not only ensure regulatory compliance but also improve traceability, operational efficiency, and overall patient safety, reinforcing automation as a key driver in the global immunohematology market.
Increasing Blood Donations and Transfusion Procedures
The increasing volume of global blood donations and subsequent transfusion procedures is a key driver of the immunohematology market, as every collected unit requires rigorous testing to ensure recipient safety. According to the World Health Organization, approximately 118.5 million blood donations are collected worldwide each year. Each unit must undergo essential immunohematology procedures, including ABO and Rh blood grouping, along with screening for transfusion-transmissible infections such as HIV, hepatitis B, and hepatitis C.
In emerging markets, government-led initiatives are significantly strengthening the blood supply. For example, in India, annual blood collection increased from 12.6 million units in 2023 to 14.6 million units in 2024, with voluntary donations accounting for nearly 75% of the total. This rise directly drives demand for immunohematology reagents and automated cross-matching systems. In developed regions, demand is largely supported by an aging population, where individuals over 60 years of age account for a substantial share of transfusions. These procedures are commonly associated with complex medical interventions such as cardiovascular surgeries, organ transplants, and the treatment of hematological malignancies, including leukemia.
As healthcare systems continue to expand globally and the need for transfusions rises, the role of immunohematology remains critical in ensuring the safety, compatibility, and reliability of the blood supply. This sustained demand reinforces the market’s importance in supporting effective transfusion practices and improving patient outcomes worldwide.
